Navigation Links
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

- First in human clinical data highlight safety profile of BSI-201 in

subjects with advanced solid tumors -

BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data supporting its lead PARP inhibitor, BSI-201, will be presented at the 2008 American Society of Clinical Oncology annual meeting in Chicago.

Findings will be presented from the first in human Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar will also present a Phase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine, temozolomide and carboplatin/paclitaxel in subjects with advanced solid tumors. The primary objective of these respective studies is to assess the safety profile of BSI-201 when used as a monotherapy and in combination with cytotoxic chemotherapy in subjects with measurable disease.

The schedule of poster presentations is as follows:

Title: First in Human Phase 1 Study of BSI-201, a Small Molecule

Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with

Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract#: 3577

Title: A Phase 1B Study Evaluating BSI-201 in Combination with

Chemotherapy in Subjects with Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract #: 3579

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
6. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... SILVER SPRING, Md. , March 29, 2017 On ... Ocrevus (ocrelizumab) to treat adult patients with relapsing forms ... (PPMS). This is the first drug approved by the ... by a health care professional.  "Multiple ... life," said Billy Dunn , M.D., director of ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), ... for the year ended December 31, 2016 after ... results are being released later than the previous ... include the operations and balances of Apicore from ... release and filing date meets TSX Venture Exchange ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... Software Market Outlook: 2016-2022" report to their offering. ... The global patient safety ... of delivery, end-user, and geography. Patient safety has ... globe. The field has developed significantly in the last decade and ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... South Hills of Pittsburgh now have easier access to the robotic-assisted total-hip ... Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital ...
(Date:3/29/2017)... ... ... VisualSP has helped over 1.5 million SharePoint users learn the content management system ... Help System for SharePoint was at the farm level. Enterprises using SharePoint Online in ... The company recently released a modified version of the Help System, VisualSP for Site ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies announced today ... the resolution to globally reduce the harmful use of alcohol set forth by ... TTB approved ingredients that when infused into alcohol, renders the alcohol liver and ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is ... Pharm.D., FASCP. The program was recently launched on March 1, and Dr. Wentz ... function. , Dr. Izabella Wentz is a licensed pharmacist and a foremost ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
Breaking Medicine News(10 mins):